Immune Thrombocytopenia (ITP)
The autoimmune disease that destroys platelets is Immune Thrombocytopenia (ITP), formerly known as idiopathic thrombocytopenic purpura or immune thrombocytopenic purpura. 1
Disease Definition and Pathophysiology
ITP is an autoimmune disorder characterized by immunologic destruction of otherwise normal platelets, typically occurring in response to an unknown stimulus 1. The disease involves multiple pathogenic mechanisms:
- Autoantibody-mediated platelet destruction: Anti-platelet autoantibodies (primarily targeting platelet glycoproteins) coat platelets, leading to accelerated clearance by tissue macrophages, predominantly in the spleen 1, 2
- Impaired platelet production: Contrary to historical understanding, platelet production is also decreased in many ITP patients, not just destruction 1
- T-cell mediated cytotoxicity: Autoreactive T cells directly destroy platelets and megakaryocytes 2, 3
- Complement activation: Contributes to platelet clearance 3
Clinical Presentation
ITP is defined by a platelet count less than 100 × 10⁹/L in the absence of other identifiable causes 1, 4. The disease can occur as:
- Primary ITP: Isolated thrombocytopenia without underlying cause
- Secondary ITP: Associated with other conditions including antiphospholipid antibody syndrome, viral infections (hepatitis C, HIV), autoimmune diseases, or certain drugs 1
Clinical manifestations range from asymptomatic to severe bleeding, including bruising, petechiae, mucosal bleeding, gastrointestinal hemorrhage, or intracranial hemorrhage 4.
Diagnostic Approach
Diagnosis is primarily one of exclusion 1. Essential evaluation includes:
- Complete blood count with peripheral blood film examination
- Patient and family history
- Physical examination
- Quantitative immunoglobulin levels 4
Bone marrow examination is unnecessary in children and adolescents with typical ITP features (grade 1B) 1. Testing for antinuclear antibodies is not necessary in pediatric evaluation (grade 2C) 1.
Treatment Framework
Initial Management - Adults
For adults with primary ITP requiring initial therapy, the most recent 2026 ASH guidelines recommend combination therapy over corticosteroids alone: either rituximab plus corticosteroids (with or without IVIG) or a thrombopoietin receptor agonist plus corticosteroids (with or without IVIG) rather than corticosteroids alone (conditional recommendation) 5.
This represents a significant evolution from the 2011 guidelines, which recommended longer courses of corticosteroids as first-line treatment (grade 2B) 1.
Initial Management - Pediatric
Children with no bleeding or mild bleeding (skin manifestations only) should be managed with observation alone regardless of platelet count (grade 1B) 1.
For pediatric patients requiring treatment:
- First-line: Single dose of IVIG (0.8-1 g/kg) or short course of corticosteroids (grade 1B) 1
- IVIG is preferred when rapid platelet increase is needed (grade 1B) 1
- Anti-D can be used in Rh-positive, nonsplenectomized children (grade 2B) 1
Second-Line Therapy - Adults
For patients who failed first-line corticosteroids, the 2026 guidelines strongly recommend a thrombopoietin receptor agonist (strong recommendation) or rituximab (conditional recommendation) 5.
The 2011 guidelines noted that splenectomy remains the only treatment providing sustained remission off all treatments at 1 year and beyond in a high proportion of patients, though rituximab sustained remission rates are disappointing (18-35% long-term response) 1.
Second-Line Therapy - Pediatric
For children with significant ongoing bleeding despite initial treatment:
Splenectomy is recommended for children with chronic or persistent ITP who have significant bleeding, lack of responsiveness to other therapies, and/or need for improved quality of life (grade 1B), but should be delayed for at least 12 months unless severe disease is present (grade 2C) 1.
Critical Caveats
- The fundamental treatment goal is achieving a platelet count that prevents major bleeding, not "normalizing" the platelet count 1
- Rituximab carries rare but serious risks including progressive multifocal leukoencephalopathy and grade 3-5 toxicity in approximately 6% of patients 1
- Treatment decisions must account for bleeding risk factors beyond platelet count alone, including age, lifestyle, and comorbidities 4
- Secondary causes must be excluded before diagnosing primary ITP 1